Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice.
Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking …

Abstract Treatment advances lead to survival benefits of patients with advanced prostate
cancer. These treatments are highly efficacious in a subset of patients; however, similarly to …

Background While it has been challenging to establish prostate cancer patient‐derived
xenografts (PDXs), with a take rate of 10‐40% and long latency time, multiple groups …

Recently, there has been renewed interest in the development and characterization of
patient-derived tumour xenograft (PDX) models. Numerous PDX models have been …

Abstract Systems that model cancer form the backbone of research discovery, and their
accuracy and validity are a key determinant to ensure successful translation. In many tumour …

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish
a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and …

Background Understanding the progression of prostate cancer to androgen‐independence/
castrate resistance and development of preclinical testing models are important for …

Prostate cancer remains a lethal disease. Preclinical cancer models that accurately
represent the tumors of the patients they are intended to help are necessary to test potential …

Background Presently,∼ 85 serially transplantable human prostate cancer xenografts
spanning the phenotypic, epigenetic, and genetic heterogeneity seen clinically are available …

Standardized and reproducible preclinical models that recapitulate the dynamics of prostate
cancer are urgently needed. We established a bank of transplantable patient-derived …